Food and Drug Administration, HHS.
This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.
Name of Committee: Cardiovascular and Renal Drugs Advisory Committee.
General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on December 8, 2003, from 8:30 a.m. to 5 p.m. and on December 9, 2003, from 8 a.m. to 4:30 p.m.
Location: Hilton, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD.
Contact Person: Dornette Spell-LeSane, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: email@example.com, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572) in the Washington, DC area), code 12533. Please call the Information Line for up-to-date information on this meeting.
Agenda: On December 8, 2003, the committee will discuss whether aspirin should be recommended for primary prevention of myocardial infarction. Professional labeling for aspirin currently recommends its use for prevention of a second myocardial infarction. On December 9, 2003, the committee will discuss new drug application (NDA) 21-526, proposed trade name Ranexa (ranolazine) 375 milligrams (mg) and 500 mg Tablets, CV Therapeutics Inc., for the proposed indication of treatment of chronic stable angina.
Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by December 2, 2003. Oral presentations from the public will be scheduled between approximately 1 p.m. and 1:30 p.m. on both days. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before December 2, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Dornette Spell-LeSane at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).Start Signature
Dated: November 10, 2003.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 03-28686 Filed 11-17-03; 8:45 am]
BILLING CODE 4160-01-S